GYRE 株価分析 — Gyre Therapeutics Inc. (Healthcare >> Biotechnology)
GYRE に関するよくある質問
GYREのPER(株価収益率)は?
Gyre Therapeutics Inc.(GYRE)は現在PER 176.09倍で取引されています。
GYREのROE(自己資本利益率)は?
Gyre Therapeutics Inc.のROEは-6.21%です。
GYREの配当利回りは?
Gyre Therapeutics Inc.の配当利回りは0.00%です。
GYREの品質スコア(Quality Score)は?
当社のAIはGYREの総合財務品質を100点中15点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
GYREは今が買い時ですか?
当社AIのタイミングスコアは100点中51点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
GYREはどのセクターに属しますか?
Gyre Therapeutics Inc.はHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
GYRE AI Analysis Summary
Our AI summary for GYRE: Gyre Therapeutics Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 176.09, ROE of -6.21%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 51/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 6.67
Price
0.27
(4.22%)
Day Change
|
|
|---|
GYRE, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
2792
|
| Magic Formula Rank by ROE |
2792
|
| Magic Formula Rank by ROIC |
2157
|
| Price | 6.67 |
| PBV / Sector |
5.21 / 5.54
|
| Earning Per Share | -0.06 |
| PE / Sector |
176.09 / 21.47
|
| PEG or PE/Growth / Sector |
-0.11 / 1.07
|
| Average 1M Daily Value |
0.32 M
GREAT
|
| Average 1W Daily Value |
0.34 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
41% |
| 登録情報 |
| Analyze Date | 2026-08-08 08:04:01 |
| Symbol | GYRE |
| Name | GYRE THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 111.49 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 713.53 / 9,564.45 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 12730 High Bluff Drive, San Diego, CA, United States, 92130
Phone: 858-284-0115
Website: https://www.gyretx.com
Employees: 625
Sector: Healthcare >> Biotechnology
Description: Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google